公开(公告)号：US10604501B2

公开(公告)日：2020-03-31

申请号：US16310305

申请日：2017-06-13

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： Arnaud Chevalier ,  Omar Khdour ,  Yanmin Zhang ,  Sidney Hecht

IPC: C07D321/00 ,  C07D311/06 ,  C07D311/58 ,  C07D403/08 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D487/14 ,  C07D493/10 ,  A61K47/54 ,  A61K49/00 ,  G01N33/58

Abstract: The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluore scent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

公开(公告)号：US11203583B2

公开(公告)日：2021-12-21

申请号：US16784202

申请日：2020-02-06

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： Arnaud Chevalier ,  Omar Khdour ,  Yanmin Zhang ,  Sidney Hecht

IPC: C07D321/00 ,  C07D311/06 ,  C07D311/58 ,  C07D403/08 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D487/14 ,  C07D493/10 ,  A61K47/54 ,  A61K49/00 ,  G01N33/58

Abstract: The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluorescent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

公开(公告)号：US10532109B2

公开(公告)日：2020-01-14

申请号：US16301888

申请日：2017-05-08

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： Shengxi Chen ,  Yanmin Zhang ,  Sidney Hecht

IPC: A61K47/68 ,  A61K38/16 ,  C07K14/31 ,  C07K16/32 ,  C07K16/30

Abstract: Provided herein are therapeutic agents having specificity for having inhibitory activity against cancer cells that overexpress human epidermal growth factor receptor (HER) genes, including therapeutic agents comprising one or more HER-targeting peptides, pharmaceutical compositions comprising such therapeutic agents, and methods of using such compositions to treat or prevent a cancer or other disease condition associated with HER overexpression.